Advertisement

Topics

Clinical Trials About "NSAV ANNOUNCES MJCOIN PRIVATE PRESALE LEGAL CANNABIS DIGITAL" RSS

11:18 EDT 18th September 2018 | BioPortfolio

We list hundreds of Clinical Trials about "NSAV ANNOUNCES MJCOIN PRIVATE PRESALE LEGAL CANNABIS DIGITAL" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "NSAV ANNOUNCES MJCOIN PRIVATE PRESALE LEGAL CANNABIS DIGITAL" on BioPortfolio

We have published hundreds of NSAV ANNOUNCES MJCOIN PRIVATE PRESALE LEGAL CANNABIS DIGITAL news stories on BioPortfolio along with dozens of NSAV ANNOUNCES MJCOIN PRIVATE PRESALE LEGAL CANNABIS DIGITAL Clinical Trials and PubMed Articles about NSAV ANNOUNCES MJCOIN PRIVATE PRESALE LEGAL CANNABIS DIGITAL for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of NSAV ANNOUNCES MJCOIN PRIVATE PRESALE LEGAL CANNABIS DIGITAL Companies in our database. You can also find out about relevant NSAV ANNOUNCES MJCOIN PRIVATE PRESALE LEGAL CANNABIS DIGITAL Drugs and Medications on this site too.

Showing "NSAV ANNOUNCES MJCOIN PRIVATE PRESALE LEGAL CANNABIS DIGITAL" Clinical Trials 1–25 of 1,000+

Extremely Relevant

Dose-response of Cannabis and Driving

Epidemiological studies have established a link between collisions while driving and cannabis use. With the changing legal landscape around cannabis, there is much interest in determining per se limits of cannabis while driving. The present study will evaluate driving on a driving simulator after smoking placebo or cannabis with 3 different levels of THC. THC is the active component in cannabis and blood, urine and oral fluid levels of THC will be correlated with driving impair...


Relevant

Investigation of Cannabis for Chronic Pain and Palliative Care

The use of cannabis for severe medical conditions is being legalized in different states, increasing the mandate to make cannabis legal for medically ill patients. However, there is a lack of placebo-controlled studies investigating the efficacy of cannabis. Dronabinol (synthetic, oral Δ-9-THC) is FDA approved for the appetite stimulation in AIDS-related anorexia and nausea/vomiting in chemotherapy patients. Nabilone, a synthetic analogue of THC, is approved for nausea/vomitin...

Nabilone in Cannabis Users With PTSD

Despite the prevalence of cannabis use among the PTSD population and self-reports that it is used to help cope with PTSD symptoms, the direct effects of cannabis on PTSD symptomology are unknown. The purpose of this placebo-controlled, within-subject study is to assess the effects of smoked cannabis and orally administered nabilone, a synthetic analog of THC, the primary psychoactive component of cannabis on multiple dimensions of PTSD symptomatology in cannabis smokers with PT...


Cannabis Use and Epigenetic Alterations in Human Male Sperm Cells

This is a follow-up project to a proof-of-concept study to determine if Cannabis use in male humans is associated with changes in DNA methylation profile of sperm. This proposal will examine the epigenome of sperm from men actively using Cannabis before and after a period of Cannabis abstinence. The results will be compared to control non-users.

Effects of THC and Alcohol on Driving Performance

Low blood concentrations of THC and alcohol appear to have a minimal effect on driving performance.However, there is a gap in the literature about the combined effects of THC and alcohol. There is little empirical evidence to determine whether the combination of THC and alcohol could be additive or multiplicative. This issue is particularly important when dealing with concentrations that are just below legal thresholds - it is important to identify if someone who may have consu...

Effect of Lorcaserin on Cannabis Withdrawal and Self-administration

In this study, the investigators are interested in testing how lorcaserin influences the effects of cannabis in a human laboratory model of cannabis use.

Combined Pharmacotherapy for Cannabis Dependency

The purpose of this study is to see if Lofexidine in combination with Marinol is superior to placebo in achieving abstinence, reducing cannabis use and reducing withdrawal in cannabis-dependent patients seeking treatment for their marijuana use.

Qualitative Analysis of Hospital Executives, Physician Administrators, and Hospital Legal Counsels' Perceptions of End-of-Life Care

Interviewing hospital executives, physician administrators and hospital legal counsel who work in a hospital setting (academic, governmental, private or community hospital) about their perceptions concerning current and future end-of-life care provided in their facilities

Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia

Cannabis use disorders are an important public health problem in the United States, but no effective pharmacotherapies are available to treat these disorders. People with schizophrenia are more likely than healthy people to abuse cannabis. Cannabis use may worsen clinical outcomes in this group, making the identification of pharmacotherapy to treat cannabis dependence in those with schizophrenia important. The investigators intend to test the combination of dronabinol, a cann...

Processing and Effects of Cannabis

The purpose of this study is to investigate the processing of cannabis, and to investigate the occurrence of effects of cannabis on the cardiovascular system and the central nervous system; at higher levels of exposure.

Cannabis Versus Oxycodone for Pain Relief

This study investigates the ability of cannabis to reduce chronic back and neck pain and to reduce sensitivity to an acute painful stimulus. Cannabis will be compared to both oxycodone and a placebo.

Biobehavioral Effects of Topiramate on Cannabis-Related Outcomes in Adolescents

Cannabis use is a significant public health concern that disproportionately affect youth. Although promising psychosocial interventions are being developed, most youth do not benefit from these interventions alone. Given the clinical demand for effective treatments, the National Institute on Drug Abuse (NIDA) identified the critical need for data on the tolerability and potential efficacy of medications in adolescents. The purpose of this two-year study is to test if and how t...

Cannabis and Schizophrenia: Self-Medication and Agonist Treatment

The first aim of this study is to determine whether a brain reward center (BRC) deficiency in patients with schizophrenia (SCZ) and cannabis use disorder (CUD) will be normalized when patients are given cannabis or dronabinol. The second aim will serve to further assess the effects of dronabinol on symptoms and medication side effects in this population.

Facilitating the Behavioral Treatment of Cannabis Use Disorder

Cannabis use disorders remain a significant public health problem. The pharmacological facilitation of behavioral treatment represents a promising strategy for addressing disordered cannabis use. Cannabis use disorders are recognized to be associated with various vulnerabilities that complicate the course of treatment and that may be amenable to glutamate modulators. The purpose of this randomized, double-blind, controlled trial is to test various glutamate modulators in conjun...

Substance Misuse To Psychiatric Disorders for Cannabis

With the recent availability of vortioxetine, and the surging phenomenon of cannabis misuses amongst young abusers, it is a timely opportunity to conduct an early pharmacotherapy intervention study to offer an evidence-based strategy aiming to stop individuals with cannabis use disorders with depressive or anxiety symptoms, to develop into a more chronic disabling dependence or co-morbid state.

Safety and Efficacy of Cannabis in Tourette Syndrome

For many individuals with Tourette syndrome (TS), available medications do not help with their symptoms, or cause significant side effects. Two small controlled trials have investigated the effect of oral delta-9-tetrahydrocannabinol (THC), a principal psychoactive ingredient of cannabis, in TS patients. While these trials have shown promising results, the effect sizes were not as large and consistent as those reported by patients with regards to inhaled cannabis (smoked or vap...

Treatment for Cannabis Withdrawal and Dependence

Cannabis is the most widely used illicit drug in the United States, and worldwide, with 1 in 10 users estimated to meet diagnostic criteria for cannabis dependence. Avoidance of withdrawal symptoms (e.g., disturbances in mood, sleep, and craving) is a common relapse precipitant. Cannabis use also impairs executive cognitive functions thereby increasing vulnerability to relapse and reducing the ability to benefit from behavioral therapy. There are no pharmacological treatments f...

Using a Field Performance Test on an iPad to Evaluate Driving Under the Influence of Cannabis

This study was authorized by the California Legislature (Assembly Bill 266, the Medical Marijuana Regulation and Safety Act (73) to help with detection of driving under the influence of cannabis. Healthy volunteers will inhale smoked cannabis with either 0% (placebo), 6.7%, or 12.6% Δ9-THC at the beginning of the day, and then complete driving simulations, iPad-based performance assessments, and bodily fluid draws (e.g., blood, saliva, breath) before the cannabis smoking and h...

Effect of Motivational Therapy on Schizophrenia With Cannabis Misuse

Schizophrenia is a severe mental illness with a lifetime morbidity risk close to 1 %, involving both genetic and environmental risk factors. Prospective studies have shown that heavy use of cannabis in adolescence moderately increases the risk of developing schizophrenia. Many data have also suggested that the co-occurrence of cannabis abuse in patients with schizophrenia has a deleterious impact on the clinical outcome of schizophrenia. Cannabis abuse by schizophrenic patients...

The UTHealth Medical-Legal Partnership: Improving Health by Addressing Health-Harming Legal Needs

The purpose of this study is to assess the acceptability, feasibility, and preliminary effectiveness of the UTHealth medical-legal partnerships (MLP) against usual care.

Progesterone for Cannabis Withdrawal

Sex and gender differences in behavioral, biological, and clinical correlates of substance use disorders are myriad, yet there exists a dearth of gender-informed treatment options. Ovarian hormones have been identified as potential mechanisms of these disparities , and recent clinical trials have begun to examine their utility as possible pharmacotherapeutic agents. The ovarian hormone progesterone has shown promise as a treatment for female cocaine and nicotine users, but has ...

Interactions Between Physical Activity and Cannabis Use in Adults

In this study the investigators will explore the relationship between physical activity and cannabis use. The investigators will compare regional brain activation detected by imaging technique(fRMI) before and after exercise in cannabis users and compare results with results from controls. The investigators hypothesize that the regional brain activation in response to visual cues (pictures related to cannabis use and food) will be different in cannabis users than in controls an...

Anxiety, Inflammation, and Stress

This study investigates whether the anxiolytic effects and anti-inflammatory properties of cannabis vary as a function of the ratio of CBD to THC, with the goal that these effects may shed light on the mixed data linking cannabis use and anxiety. Individuals with mild to moderate anxiety who elect to use cannabis (smoked flower or edible) will complete four weeks of observation. Participants complete cognitive tasks, a substance use history, health questionnaires concerning sle...

Cannabidiol Pharmacotherapy for Adults With Cannabis Use Disorder

We aim to determine Epidiolex's promise as a pharmacotherapy for cannabis use disorder. We hypothesize that Epidiolex, when added to medical management, will result in greater reductions in marijuana use compared to placebo as measured by our 2 primary outcome measures: 1) quantitative THC levels and 2) self-report by Timeline Follow Back. Secondary outcome measures will include treatment retention, patient satisfaction, cannabis withdrawal, cannabis craving, depressive symptom...

Cannabis Oil for Pain in Parkinson's Disease

Full Title: A phase II, randomized, open-label, double-blind, two-center study to evaluate the tolerability, safety and dose-finding of oil cannabis preparation for pain in Parkinson's disease. Short title: Cannabis oil for pain in Parkinson's disease Sample Size: N = 15 Study Population: Patients with Parkinson's disease and pain, without cognitive impairment. Study Duration: July 2018 - July 2019 Study Agent/ Intervention: Cannabis oil: mixed oil cannabis preparation...


More From BioPortfolio on "NSAV ANNOUNCES MJCOIN PRIVATE PRESALE LEGAL CANNABIS DIGITAL"

Advertisement
Quick Search
Advertisement
Advertisement